Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded silence and non-establishment

Show, for each medicine and tracked question, whether the recorded source sections contain an answer, explicitly say the question is not established, or stay silent.

What this does not mean: SILENT means only that this corpus did not record an answer from the sections it read. It is not evidence of safety, danger, or real-world absence. NOT_ESTABLISHED is an explicit source state and must not be collapsed into silence.
Public rows
167,535
Generated
Schema version
1.2.0

Coverage

What this run contains

Medicine-question rows
167,535
Medicines
9,855
Questions
17
Recorded
19,750
Not established
1,463
Silent
146,322
explicit not established
1,463
source read no answer
0
no qualifying source read
146,322
source kind not machine verifiable
0
source recorded no qualifying read
0

Method

How the rows were made

  1. A fixed 17-question set is applied deterministically to each medicine record.
  2. RECORDED, NOT_ESTABLISHED, and SILENT remain distinct. Population mentions without a finding stay RECORDED but carry mentionedWithoutFinding=true.
  3. Each row is joined only when the ledger persists a source identifier for that occurrence and the same source object is attached to that exact question field or statement collection. An excerpt elsewhere in the medicine envelope cannot establish that this question was read.
  4. A source counts only when its kind, identifier, label, and retrieval date satisfy the checked-in background-source contract. SOURCE_READ_NO_ANSWER additionally requires that exact persisted binding, a nonblank excerpt, and a canonical machine-verifiable locator.
  5. This projection includes every medicine-question pair, every source identifier emitted by the ledger, and the complete exact-scope source records; it does not copy review-work fields.

Limits

Read these before using a row

  • SILENT means no source in this corpus, in the sections that were read, states an answer. It is a fact about the documents recorded here and never a fact about the medicine.
  • A record silent on a question is not evidence that no answer exists, and it is not evidence of safety or of danger in either direction. A label that never states a pediatric half-life is a label that never states one, nothing more.
  • Section scoping is a real limit. A fact can sit in a section the extractor does not read, so every silence count should be read as "not recorded from the sections read" rather than "not stated anywhere".
  • Silence on the boxed-warning question is the clearest case of this: 9183 of 9855 records hold no boxed-warning statement, which means no recorded document contributed one, not that no boxed warning exists.
  • Only the 6 population questions can show NOT_ESTABLISHED, because only population statements carry a source-stated evidence state. On the other 11 questions a source sentence saying something was never determined, if one was printed, arrives here as a plain absence and is counted as SILENT.
  • 3278 of 9855 records were produced by the deterministic label parser rather than assembled by a person. The parser reads a fixed set of sections, so its silences are more often a limit of the parser than of the source; the roll-up splits recorded and silent counts by tier so the two are never added together blindly.
  • RECORDED on a population question merges two different answers: a source reporting a finding in the group, and a source that only raises the group without settling safety or effectiveness for it. 88% of recorded population answers here are the second kind, so a high recorded share on those questions is not a high share of settled answers. Entries of the second kind carry mentionedWithoutFinding and the roll-up counts them in recordedMentionOnly.
  • Where the recorded statements for one population disagree, one saying a group was studied and another saying the question was not established, the entry counts as RECORDED and is marked as holding mixed states. The disagreement is recorded and is not settled here.
  • Counts are over the records this corpus holds, which is neither every medicine nor every revision of every document. The recorded share of a question is a property of this corpus on this run date.
  • A source object without an excerpt is provenance, not proof that the exact section was read. It therefore cannot become SOURCE_READ_NO_ANSWER.
  • An excerpt attached to another question or module is unrelated evidence for this classification and is never used to label this row as read.
  • The current ledger does not persist a section-read binding for SILENT occurrences, so those rows remain NO_QUALIFYING_SOURCE_READ. SOURCE_READ_NO_ANSWER stays empty until a future artifact records an exact question-and-source binding; answer-bearing consensus evidence is never repurposed as proof of silence.
  • SOURCE_KIND_NOT_MACHINE_VERIFIABLE reports only the absence of a canonical locator in the checked-in source-fetch contract. It does not judge the source itself.

Provenance

Source examples

Abaloparatide · population_pediatric · NOT_ESTABLISHED

EXPLICIT_NOT_ESTABLISHED. Do the recorded documents address a pediatric population?

FDA_LABEL:712143d9-e21e-4013-bb3b-3426a21060a8

0.01-0.2 Mole Percent Bisacrylamide) · half_life · SILENT

NO_QUALIFYING_SOURCE_READ. Do the recorded documents state an elimination half-life?

Artifact used for this view: data/agents/current/silence-ledger.json + data/recorded-background.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name.
questionIdstringStable identifier from the fixed question set.
questionstringThe exact corpus-coverage question.
modulestringRecorded-background module checked for an answer.
statestringRECORDED, NOT_ESTABLISHED, or SILENT.
silenceMeaningstringExplicit non-establishment or the exact source-read boundary behind SILENT; null for RECORDED.
mentionedWithoutFindingbooleanTrue when a population was mentioned without a settled finding.
sourceIdentifiersstring[]Exact recorded source bindings; empty for SILENT.
scopedSourcessource[]Complete valid source objects attached to this exact question field or statement collection, including version/effective date or explicit absence, with safe allowlisted links when a canonical adapter exists.
recordedSourceCountnumberDistinct qualifying source kind-and-identifier pairs attached to this exact question scope.
recordedSourceKindsstring[]Qualifying source kinds attached to this exact question scope.
machineVerifiableSourceKindsstring[]Exact-scope recorded kinds for which the checked-in source-fetch contract defines a canonical locator.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact state; NOT_ESTABLISHED is never treated as SILENT.

Exact derived source-read boundary; RECORDED rows have no silence meaning.

Exact question identifier.

Clear

Showing 1,631–1,640 of 167,535 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1631

    Medicine slug
    abelmoschus-moschatus-seed
    Medicine name
    Abelmoschus Moschatus Seed
    Question key
    population_hepatic_impairment
    Question
    Do the recorded documents address hepatic impairment?
    Module
    populationStatements[HEPATIC_IMPAIRMENT]
    State
    SILENT
    Silence meaning
    NO_QUALIFYING_SOURCE_READ
    Mention only
    No
    Source identifiers
    None recorded
    Exact question sources
    None recorded
    Recorded source documents
    0
    Recorded source kinds
    None recorded
    Machine-verifiable source kinds
    None recorded

  2. Projected row 1632

    Medicine slug
    abelmoschus-moschatus-seed
    Medicine name
    Abelmoschus Moschatus Seed
    Question key
    population_renal_impairment
    Question
    Do the recorded documents address renal impairment?
    Module
    populationStatements[RENAL_IMPAIRMENT]
    State
    SILENT
    Silence meaning
    NO_QUALIFYING_SOURCE_READ
    Mention only
    No
    Source identifiers
    None recorded
    Exact question sources
    None recorded
    Recorded source documents
    0
    Recorded source kinds
    None recorded
    Machine-verifiable source kinds
    None recorded

  3. Projected row 1633

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    half_life
    Question
    Do the recorded documents state an elimination half-life?
    Module
    pharmacokinetics.halfLife
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Elimination The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  4. Projected row 1634

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    bioavailability
    Question
    Do the recorded documents state a bioavailability?
    Module
    pharmacokinetics.bioavailability
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Absorption The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV).
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  5. Projected row 1635

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    t_max
    Question
    Do the recorded documents state a time to maximum concentration?
    Module
    pharmacokinetics.tMax
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      The median T max of abemaciclib is 8.0 hours (range: 4.1-24.0 hours).
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  6. Projected row 1636

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    protein_binding
    Question
    Do the recorded documents state plasma protein binding?
    Module
    pharmacokinetics.proteinBinding
    State
    SILENT
    Silence meaning
    NO_QUALIFYING_SOURCE_READ
    Mention only
    No
    Source identifiers
    None recorded
    Exact question sources
    None recorded
    Recorded source documents
    0
    Recorded source kinds
    None recorded
    Machine-verifiable source kinds
    None recorded

  7. Projected row 1637

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    volume_of_distribution
    Question
    Do the recorded documents state a volume of distribution?
    Module
    pharmacokinetics.volumeOfDistribution
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      The geometric mean systemic volume of distribution is approximately 690.3 L (49% CV).
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  8. Projected row 1638

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    mechanism_of_action
    Question
    Do the recorded documents describe how the medicine acts?
    Module
    mechanism.statements
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).
    2. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      These kinases are activated upon binding to D-cyclins.
    3. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation.
    4. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis.
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  9. Projected row 1639

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    molecular_identity
    Question
    Do the recorded documents state a molecular formula or molecular weight?
    Module
    molecularIdentity
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      It is a white to yellow powder with the empirical formula C 27 H 32 F 2 N 8 and a molecular weight 506.59.
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

  10. Projected row 1640

    Medicine slug
    abemaciclib
    Medicine name
    Abemaciclib
    Question key
    metabolic_handling
    Question
    Do the recorded documents name an enzyme or transporter that handles the medicine?
    Module
    interactionSignals
    State
    RECORDED
    Silence meaning
    Not recorded
    Mention only
    No
    Source identifiers
    • FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06
    Exact question sources
    1. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      P-gp and BCRP Inhibitors : In vitro, abemaciclib is a substrate of P-gp and BCRP.
    2. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib inhibits P-gp and BCRP.
    3. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      The effect of P-gp or BCRP inhibitors on the pharmacokinetics of abemaciclib has not been studied.
    4. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib is a substrate of P-gp and BCRP.
    5. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      The clinical consequences of this finding on sensitive P-gp and BCRP substrates are unknown.
    6. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      CYP Metabolic Pathways: In a clinical drug interaction study in patients with cancer, multiple doses of abemaciclib (200 mg twice daily for 7 days) did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 substrates.
    7. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed.
    8. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      In Vitro Studies Transporter Systems : Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage.
    9. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      The observed serum creatinine increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via OCT2, MATE1, and MATE2-K [see Adverse Effects ( 6.1 )] .
    10. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Metformin: In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage) increased metformin AUC 0-INF by 37% and C max by 22% relative to metformin alone.
    11. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib and its major metabolites at clinically relevant concentrations do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake transporters OAT1 and OAT3.
    12. FDA_LABELRetrieved 2026-08-30
      FDA_LABEL:be4bc0de-0fdc-4d46-8d25-be43c79e6a06 (opens source in a new tab)

      Abemaciclib label

      Version not recorded · Effective date not recorded

      Abemaciclib and its major active metabolites, M2 and M20, are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3.
    Recorded source documents
    1
    Recorded source kinds
    • FDA_LABEL
    Machine-verifiable source kinds
    • FDA_LABEL

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/silence-ledger?limit=10&offset=1630

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact state; NOT_ESTABLISHED is never treated as SILENT.Values: RECORDED, NOT_ESTABLISHED, SILENT
meaning
Exact derived source-read boundary; RECORDED rows have no silence meaning.Values: EXPLICIT_NOT_ESTABLISHED, SOURCE_READ_NO_ANSWER, NO_QUALIFYING_SOURCE_READ, SOURCE_KIND_NOT_MACHINE_VERIFIABLE, SOURCE_RECORDED_NO_QUALIFYING_READ
field
Exact question identifier.Values: half_life, bioavailability, t_max, protein_binding, volume_of_distribution, mechanism_of_action, molecular_identity, metabolic_handling, boxed_warning, contraindications, most_common_adverse_reactions, population_pediatric, population_geriatric, population_pregnancy, population_lactation, population_hepatic_impairment, population_renal_impairment
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy